soul trial oral semaglutide cardiovascular outcomes results 2024 nejm (NEJM 2025): led to a 14% ↓ in major CV events vs placebo in T2DM with ASCVD or CKD — no ↑ in serious AEs. #Semaglutide #CardioDiabetes #updatesinmedicine Trial Scorecard: SOUL

Reading the GLP-1 Evidence Honestly The disciplined position, for a provider or an investor trying to see this clearly, is to hold two facts at once

Tfh, follicular helper T cell

Rapid weight loss Jennifer Hardy Jun 97 min read AstraZeneca Moves Toward the Oral GLP-1 Market with Elecoglipron The race to develop effective oral GLP-1 medications for obesity is heating up, and AstraZeneca is officially making its move

Sometimes a medication prescribed primarily for diabetes, but containing the same active ingredient as a weight loss drug, may be covered

Be sure to inform your doctor if you have a history of: Kidney disease Liver problems Severe gastrointestinal disease Partner with Healthon for Personalized Care Starting a medical weight-loss journey is easier with expert support

What The Data Shows On Regain (STEP-1 Extension